Valuation: ValiRx plc

Market Cap 2.11M 2.81M 2.47M 2.3M 3.97M 270M 4.02M 27.34M 10.68M 133M 10.55M 10.32M 460M P/E 2024
-0.53x
P/E 2025 -0.62x
Enterprise Value 1.32M 1.76M 1.55M 1.44M 2.48M 169M 2.52M 17.11M 6.68M 83.31M 6.6M 6.46M 288M EV / Sales 2024
27,264,249x
EV / Sales 2025 54,121,446x
Free-Float
93.4%
Yield 2024 *
-
Yield 2025 -
1 month-3.03%
3 months-42.86%
6 months-58.44%
Current year-52.24%
1 week 0.15
Extreme 0.15
0.17
1 month 0.13
Extreme 0.13
0.18
Current year 0.13
Extreme 0.13
0.48
1 year 0.13
Extreme 0.13
0.85
3 years 0.13
Extreme 0.13
15
5 years 0.13
Extreme 0.13
65
10 years 0.13
Extreme 0.13
1,436.25
Manager TitleAgeSince
Chief Executive Officer 55 12/08/2024
Director of Finance/CFO 81 -
Chief Tech/Sci/R&D Officer - 27/03/2025
Director TitleAgeSince
Director/Board Member 81 01/09/2006
Chairman 59 25/07/2024
Director/Board Member 55 12/08/2024
Date Insider Type Main position Quantity % Market Cap.
3/4/26 A Buy

Chief Executive Officer

1,000,000 0.1346%
10/18/22 A Free

Director

75,000 0.0832%
10/18/22 A Free

Director

75,000 0.0832%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-73.33%-97.63% 2.82M
-1.82%+5.03%+56.71%+66.69% 57.28B
-0.27%+5.74%+40.26%+80.17% 54.99B
-2.05%-3.31%+0.75%+414.39% 23.18B
+1.97%-0.43%-21.00%-13.67% 22.59B
-1.13%+4.54%+22.73%-8.06% 20.46B
+1.57%+2.09%+28.01%-27.56% 17.56B
-0.10%+5.57%+38.63%+565.16% 15.67B
+5.29%0.00%+185.09%+332.66% 14.46B
+0.79%-0.20%+22.39%+181.58% 13.92B
Average +0.50%+1.45%+30.02%+149.37% 24.01B
Weighted average by Cap. -0.06%+1.93%+39.80%+137.72%

Financials

2024 2025
Net sales 0.05 0.07 0.06 0.05 0.09 6.35 0.09 0.64 0.25 3.14 0.25 0.24 10.84 0.03 0.04 0.04 0.03 0.06 4 0.06 0.41 0.16 1.98 0.16 0.15 6.83
Net income -1.92M -2.55M -2.24M -2.09M -3.6M -244M -3.64M -24.79M -9.68M -121M -9.57M -9.36M -417M -2.23M -2.97M -2.61M -2.43M -4.19M -285M -4.25M -28.89M -11.28M -141M -11.15M -10.91M -486M
Net Debt -1.54M -2.05M -1.81M -1.68M -2.9M -197M -2.94M -19.99M -7.81M -97.29M -7.71M -7.55M -336M -790K -1.05M -924K -860K -1.48M -101M -1.5M -10.23M -3.99M -49.79M -3.95M -3.86M -172M
Logo ValiRx plc
ValiRx Plc is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of science into impactful medicines to improve patient lives. The Company provides the scientific, financial, and commercial framework for enabling rapid translation of science into clinical development. The Company selects and incubates novel drug candidates and guides them through an optimized process of development, from pre-clinical studies to clinical and investor-ready assets. Its product pipeline includes VAL201, VAL301, CLX001 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. CLX001 is a peptide in nanoparticle formulation and is designed for precision destruction of cancer cells to avoid excessive side effects.
Employees
11
Date Price Change Volume
27/07/26 GBX 0.1600 0.00% 993,575
24/07/26 GBX 0.1600 0.00% 700,567
23/07/26 GBX 0.1600 0.00% 4,728,418
22/07/26 GBX 0.1600 -3.03% 455,655
21/07/26 GBX 0.1650 0.00% 2,898,349

Annual profits - Rate of surprise